MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients...
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formaat: | Journal article |
| Taal: | English |
| Gepubliceerd in: |
Future Medicine
2021
|
| _version_ | 1826263995350253568 |
|---|---|
| author | Verstovsek, S Chen, C-C Egyed, M Ellis, M Fox, L Goh, YT Gupta, V Harrison, C Kiladjian, J-J Lazaroiu, MC Mead, A McLornan, D McMullin, MF Oh, ST Perkins, A Platzbecker, U Scheid, C Vannucchi, A Yoon, S-S Kowalski, MM Mesa, RA |
| author_facet | Verstovsek, S Chen, C-C Egyed, M Ellis, M Fox, L Goh, YT Gupta, V Harrison, C Kiladjian, J-J Lazaroiu, MC Mead, A McLornan, D McMullin, MF Oh, ST Perkins, A Platzbecker, U Scheid, C Vannucchi, A Yoon, S-S Kowalski, MM Mesa, RA |
| author_sort | Verstovsek, S |
| collection | OXFORD |
| description | Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB. |
| first_indexed | 2024-03-06T20:00:44Z |
| format | Journal article |
| id | oxford-uuid:27340fab-db42-46a2-88cc-b3546f3445fc |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:00:44Z |
| publishDate | 2021 |
| publisher | Future Medicine |
| record_format | dspace |
| spelling | oxford-uuid:27340fab-db42-46a2-88cc-b3546f3445fc2022-03-26T12:05:35ZMOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemicJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:27340fab-db42-46a2-88cc-b3546f3445fcEnglishSymplectic ElementsFuture Medicine2021Verstovsek, SChen, C-CEgyed, MEllis, MFox, LGoh, YTGupta, VHarrison, CKiladjian, J-JLazaroiu, MCMead, AMcLornan, DMcMullin, MFOh, STPerkins, APlatzbecker, UScheid, CVannucchi, AYoon, S-SKowalski, MMMesa, RAHallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB. |
| spellingShingle | Verstovsek, S Chen, C-C Egyed, M Ellis, M Fox, L Goh, YT Gupta, V Harrison, C Kiladjian, J-J Lazaroiu, MC Mead, A McLornan, D McMullin, MF Oh, ST Perkins, A Platzbecker, U Scheid, C Vannucchi, A Yoon, S-S Kowalski, MM Mesa, RA MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic |
| title | MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic |
| title_full | MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic |
| title_fullStr | MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic |
| title_full_unstemmed | MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic |
| title_short | MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic |
| title_sort | momentum momelotinib vs danazol in patients with myelofibrosis previously treated with jaki who are symptomatic and anemic |
| work_keys_str_mv | AT verstovseks momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT chencc momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT egyedm momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT ellism momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT foxl momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT gohyt momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT guptav momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT harrisonc momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT kiladjianjj momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT lazaroiumc momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT meada momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT mclornand momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT mcmullinmf momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT ohst momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT perkinsa momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT platzbeckeru momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT scheidc momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT vannucchia momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT yoonss momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT kowalskimm momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic AT mesara momentummomelotinibvsdanazolinpatientswithmyelofibrosispreviouslytreatedwithjakiwhoaresymptomaticandanemic |